Abilify Adds Bipolar Maintenance Claim And Cerebrovascular Warning
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol-Myers Squibb/Otsuka's atypical antipsychotic becomes second drug in class, after Lilly's Zyprexa, with bipolar maintenance indication. Abilify also joins Zyprexa and J&J's Risperdal with warning on cerebrovascular adverse events in elderly dementia patients.
You may also be interested in...
Pravachol Faces Erosion, But Favorable Rebates Yield Q2 Sales Gain
Bristol-Myers Squibb’s cholesterol-lowering agent benefits from lower Medicaid and managed care rebate rates, helping drive 8% sales gain in U.S.
Pravachol Faces Erosion, But Favorable Rebates Yield Q2 Sales Gain
Bristol-Myers Squibb’s cholesterol-lowering agent benefits from lower Medicaid and managed care rebate rates, helping drive 8% sales gain in U.S.
Antipsychotic "Black Box" Warning Will Caution Against Off-Label Use In Dementia
FDA is requesting class labeling describing clinical trial results that show a higher rate of mortality in patients treated with atypical antipsychotics for dementia-related behavioral disorders compared to placebo. FDA's public health advisory and physician alert affect seven products.